About this trial
Lung cancer is the leading cause of mortality in the world, and also in Taiwan.Despite the researches and availability in new therapies, it causes the highest mortality and is one of the most preventable cancers as well. Smoking is the most common cause of lung cancer worldwide. Compared to lung cancer in smokers, lung cancer in never-smokers is associated with East Asian ethnicity, female sex, and adenocarcinoma histology. This unique risk group is likely to have distinct molecular drivers, especially EGFR, ALK, and ROS1 mutations.In National Taiwan Cancer Registry data, more than half (53%) of all newly diagnosed lung cancer patients and 93% of female patients are lifelong never-smokers. This scenario is common in East Asia. It is essential to develop a different strategy for screening lung cancer patients with other high-risk profiles. Several risk factors have been identified in never-smoking lung cancer and one of the most important factor is a lung cancer family history (LCFH) in a first-degree relative. Other high-risk occupational or environmental factors include air-pollution exposed occupations (such as traffic policeman and street cleaners) for at least 10 years, cooking index ≥ 110, defined as 2/7 \* days cooking by pan frying, stir frying, or deep frying in one week \* years cooking, cooking without using ventilation, passive smoke exposure, and history of pulmonary tuberculosis or chronic obstructive pulmonary disorders.
As described above, three high risk groups are interested in this study, the previous heavy smokers (group 1); those who has family history (group 2) and those who have high risk occupation or environment factors (group 3). From the published researches, we assume the detection rate to be 1.1% for group 1 based on NLST results16, 2.6% for group 2 (395 out of 12,011 subjects in TALENT), and we assume the detection Group 3 to be 1% after consulting board-certified senior specialists in this field.
This is a prospective, multi-center, single arm study in Taiwan of subjects who are eligible to receive LDCT screening based on recommendation of Health Promotion Administration of Taiwan.
The primary objective of TRIO part A is the LDCT screening acceptance rate of high lung cancer risk subjects.
The primary objective of TRIO part B is the exact lung cancer detection rates in these three groups.
Other secondary objectives are also included.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Cigarette smoking of at least 20 pack-years
With successful smoking cessation history (stopping smoking for more than 6 months), but less than 15 years
aged more than 50 years
age less than 50 years old, but older than the age at diagnosis of the youngest lung cancer proband in the family
Disqualifiers
previous history of lung cancer
another malignancy except for cervical carcinoma in situ or non-melanomatous carcinoma of the skin within 5 years
an inability to tolerate transthoracic procedures or thoracotomy
chest CT examination was performed within 18 months
Trial population
High risk population for lung cancer
Trial design
Cohort
Prospective
Treatments tested in this trial
Low dose computed tomography
Diagnostic test1. Participants belonging to modified Lung RADS category 1 and 2 at baseline screening will undergo the LDCT next year after the discussion with the physicians in charge. 2. Participants with nodules belonging to modified Lung RADS category 3 and 4, growing nodules, or new nodules found on follow-up LDCT scans will undergo repeat CT every 3 to 6 months or be referred for diagnostic workup depending on the size and characteristics of the nodules as the regular clinical practice. 3. Volume doubling time (VDT) will be performed in the special groups with Lung RADS category 3 or 4, but the nodules with solid components ≧ 6mm and \< 9mm. A repeat LDCT scan will be performed around 3 months after the baseline screening. 4. Check total bilirubin, urinary heavy metals,CRP, serum tumor marker, including CEA, alpha-fetal protein, etc. 5. Check pulmonary function test.
Treatment groups
Trial outcomes
Primary outcomes
The rate of willingness and completeness of LDCT screening after the detailed questionnaire survey for the eligible participants.
1. Eligible participants must meet the inclusion and exclusion criteria of this study 2. Only the one who completes the detailed questionnaire survey is counted.
To investigate overall lung cancer detection rate of high lung cancer risk individuals
Cytological or Pathological proof of lung cancer to investigate the overall lung cancer detection rate
Sponsors and contacts
Click on the lead sponsor to view all of their trials.